" class="no-js "lang="en-US"> Ong Siew Hwa - Medtech Alert
Friday, September 26, 2025
Ong Siew Hwa

Ong Siew Hwa

About Ong Siew Hwa

(A) Industrialist in molecular diagnostics & pharmaceuticals

Trained & worked in Singapore, US, Canada, including in public research institutes, hospitals, big pharma & startup company.

1. Technical

Cancer biology (signal transduction: kinases, GTPases, PI3-kinase, protein-protein interactions; genetics & genomics: mutations, gene signatures, PCR-based detection; cell-based & animal models); applications in drug development (targets, assays, biomarkers).

2. Pharmaceutical R&D

Translational research in Oncology, Kinases, Epigenetics, cancer target identification & validation, biomarker discovery, genomics, proteomics, assay development, pre-clinical compound testing.

3. Molecular diagnostics

Assay development & clinical validation.

4. Specialty areas

(i) Translational research in target identification & validation (kinases & epigenetics); disease target mechanisms of action; biomarker discovery; assay development; clinical development; prototyping

(ii) Disease areas: cancer, diabetes, infectious diseases

(B) Teaching (National University of Singapore)

1. Undergraduate: Tumor Biology; Cancer Stem Cells

2. Post-graduate: Bio-innovation & Entrepreneurship; Biologics

(C) Other interests

1. Council member of BioSingapore & Singapore Manufacturing Federation

2. Non-profit groups for communities, have set up:

(i) Science Explorers’ Camp

A school holiday camp for children from families below socio-economic norm (2010 – present).

(ii) Eating Well in Your Golden Years

A mal-nutrition risk screening program for senior citizens in the community (2013 – present).

(iii) Asian Youth Biotechnology Network (AYBN).

3. Mentoring young scientists & entrepreneurs.

4. Reading broadly, seminars, running, cooking.

Related Story

Acumen Diagnostics' PCR Capabilities to Tackle Omicron COVID-19 Variant

December 3 2021

Homegrown medical technology Company, Acumen Diagnostics Pte. Ltd. (“Acumen Diagnostics” or the “Company”), a 51% […]